Results 61 to 70 of about 45,933 (222)

SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation

Translational Oncology
Breast cancer remains the most prevalent cancer in women globally, posing significant challenges in treatment due to the inevitable development of resistance to targeted therapies like everolimus, an mTOR inhibitor. While several mechanisms of resistance
Jie-Ning Li, Zhu-Jun Loh, Hui-Wen Chen, I-Ying Lee, Jui-Hung Tsai, Pai-Sheng Chen   +5 more
doaj   +1 more source

The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino, Hagar Cohen, Bruria Hirsh Raccah, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +5 more
wiley   +1 more source

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial. [PDF]

The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses. We randomly assigned
Martinez, M, Cameron, D, Legouffe, E., Chabaud, S, Canon, J-L, Brunt, M., Bliss, J., Brunt, M, Dalenc, F, Kaluzinski, L, Lemonnier, J., Hardy-Bessard, A-C, Mouret-Reynier, M.-A., Mouret-Reynier, M-A, Andre, F, Cottu, P, Bachelot, T., Giacchetti, S, Cameron, D., Barthelemy, P., Allouache, D., Saint-Ghislain, M., Dalenc, F., Mailliez, A, Mailliez, A., Hardy-Bessard, A.-C., Kaluzinski, L., Cottu, P., Saint-Ghislain, M, Giacchetti, S., Chabaud, S., Bliss, J, Lemonnier, J, Barthelemy, P, Allouache, D, Grenier, J, Andre, F., Legouffe, E, Bachelot, T, Martinez, M., Grenier, J., Canon, J.-L.   +41 more
core   +1 more source

Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now? [PDF]

, 2013
The efficacy of everolimus with reduced cyclosporine in de novo heart transplant patients has been demonstrated convincingly in randomized studies. Moreover, everolimus-based immunosuppression in de novo heart transplant recipients has been shown in two ...
Barten, Markus J, Turazza, Fabio M., Zuckermann, Andreas, Segovia, Javier, Sigurdardottir, Vilborg, Epailly, Eric, Potena, Luciano, Varnous, Shaida, Lejmkuhl, Hans B., Wang, Shoei-Shen   +9 more
core   +3 more sources

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms

Endocrine Connections, 2019
Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD ...
Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas, Anna Koumarianou   +7 more
doaj   +1 more source

Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. [PDF]

PLoS ONE, 2017
Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. The BOLERO-2 trial showed that everolimus-exemestane achieves increased progression free survival (PFS) compared with exemestane.
Tomas Pascual, María Apellániz-Ruiz, Cristina Pernaut, Cecilia Cueto-Felgueroso, Pablo Villalba, Carlos Álvarez, Luis Manso, Lucia Inglada-Pérez, Mercedes Robledo, Cristina Rodríguez-Antona, Eva Ciruelos   +10 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Experimental Hematology & Oncology, 2018
Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.
Charles McCrea, Sukhvinder Johal, Shuo Yang, Justin Doan   +3 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Everolimus in Heart Transplantation: An Update

Journal of Transplantation, 2013
The evidence base relating to the use of everolimus in heart transplantation has expanded considerably in recent years, providing clinically relevant information regarding its use in clinical practice. Unless there are special considerations to take into
Stephan W. Hirt, Christoph Bara, Markus J. Barten, Tobias Deuse, Andreas O. Doesch, Ingo Kaczmarek, Uwe Schulz, Jörg Stypmann, Assad Haneya, Hans B. Lehmkuhl   +9 more
doaj   +1 more source